|
Post by oldfishtowner on Oct 10, 2017 12:34:55 GMT -5
Al saod he would sell for less then $125 a share pre-split..so $125 x 5 for buyout? Al will never see that price... and none of us has any better chance of seeing it. There has been massive dilution sense then as well as shedding of assets. Silly to bring that up. I don't know about the $625, but I do think I will live to see $300/share. And that's fine with me.
|
|
|
Post by sla55 on Oct 10, 2017 12:39:08 GMT -5
Good Morning MannKind! Love seeing the upper end of the day range at $6.96 Now that would be fantastic if we actually closed above $7.00.
There is serious blood in the water. Not sure what is going on but it seems that Mike has been like the wizard working behind the curtain and SHORTLY something good will be revealed. I'm still in Kansas which is the land Oz but evidently Mike MannKind and his team have hit the big stage and will move in front of the curtain SHORTLY.
GTLA...... Al saod he would sell for less then $125 a share pre-split..so $125 x 5 for buyout? Wasn't it $25 pre-split? " It’s been five years since Mann told FORBES that Afrezza would be one of the “most valuable products ever.” But he still insists he wouldn’t sell Mannkind for $25 a share even though it trades today at around $5.50, for a $700 million valuation."
|
|
|
Post by cjc04 on Oct 10, 2017 12:41:25 GMT -5
There's a possibility (maybe slight) that this is the beginning of Mannkind being a big pharm player. If inhalation has become a new better way for drug intake, well look out, Mannkind may have many forms of revenue taking up many areas of multibillion dollar markets. Sanofi did a lot of expansion by buying up pharmaceutical companies with good pipelines. If Mannkind gets big enough, with proper management...who knows, maybe it gets close to the 125 billion market caps of the big pharm companies. That's a price of 1,250 with probably many quarterly dividends along the way. I'm very happy to see that I'm no longer the dreamer because I have a $16.50 target...
|
|
|
Post by joeypotsandpans on Oct 10, 2017 12:45:05 GMT -5
There's a possibility (maybe slight) that this is the beginning of Mannkind being a big pharm player. If inhalation has become a new better way for drug intake, well look out, Mannkind may have many forms of revenue taking up many areas of multibillion dollar markets. Sanofi did a lot of expansion by buying up pharmaceutical companies with good pipelines. If Mannkind gets big enough, with proper management...who knows, maybe it gets close to the 125 billion market caps of the big pharm companies. That's a price of 1,250 with probably many quarterly dividends along the way. As the company becomes a viable player, as much as many feel they wouldn't want a BO, reality is every asset has a price. I like that Mike is from Amgen and most likely did not burn any bridges as he seems to be very professional and a class individual. Amgen lost out to Gilead in buying one of the brightest up and coming players in the oncology space. It wouldn't surprise me with the deep pockets that Amgen has if they get intimate with the technology and proprietary rights that they get interested in this up and coming pearl. This is strictly my opinion but Amgen is still best in class of the top tier biotechs and with the label change further validating the technology could get attracted to this asset, if not someone else definitely will be. All I know is I definitely want to be an owner when they come calling
|
|
|
Post by babaoriley on Oct 10, 2017 12:45:46 GMT -5
Sla, I think Al did say he wouldn't sell for less than $125 pre-split, so that would be $625, but there has been so much water under and over the bridge since that comment was made, it's virtually meaningless today. In fact, I think the bridge was washed away and we've been using a makeshift pontoon bridge for quite a while.
|
|
|
Post by sla55 on Oct 10, 2017 13:45:19 GMT -5
|
|
|
Post by nadathing on Oct 10, 2017 13:56:34 GMT -5
Good Morning MannKind! Love seeing the upper end of the day range at $6.96 Now that would be fantastic if we actually closed above $7.00.
There is serious blood in the water. Not sure what is going on but it seems that Mike has been like the wizard working behind the curtain and SHORTLY something good will be revealed. I'm still in Kansas which is the land Oz but evidently Mike MannKind and his team have hit the big stage and will move in front of the curtain SHORTLY.
GTLA...... Al saod he would sell for less then $125 a share pre-split..so $125 x 5 for buyout? Al is deceased. I think while he was alive he overestimated Afrezza's acceptance and underestimated how corrupt the FDA was.
|
|
|
Post by itellthefuture777 on Oct 10, 2017 14:53:00 GMT -5
Al saod he would sell for less then $125 a share pre-split..so $125 x 5 for buyout? Al is deceased. I think while he was alive he overestimated Afrezza's acceptance and underestimated how corrupt the FDA was. Al will be proven right..watch!
|
|
|
Post by dreamboatcruise on Oct 10, 2017 15:50:52 GMT -5
Al will never see that price... and none of us has any better chance of seeing it. There has been massive dilution sense then as well as shedding of assets. Silly to bring that up. I don't know about the $625, but I do think I will live to see $300/share. And that's fine with me. Just curious, what is the market cap you are predicting... or equivalently, how many shares outstanding... when in your mind it might reach $300/sh?
|
|
|
Post by oldfishtowner on Oct 10, 2017 16:04:02 GMT -5
I don't know about the $625, but I do think I will live to see $300/share. And that's fine with me. Just curious, what is the market cap you are predicting... or equivalently, how many shares outstanding... when in your mind it might reach $300/sh? I think I have another 20 years or so in me. So may statement is that, unless the company is bought out by then, I will live to see MNNKD at $300/share. It's a swag without any computation or much thought other than if only because of inflation and a product that should produce in excess of $4 billion annual revenue in today's dollars, it seems like an easy bet. However, I do think that $300/share will come sooner than 20 years. Much sooner.
|
|
|
Post by dreamboatcruise on Oct 10, 2017 16:16:05 GMT -5
Just curious, what is the market cap you are predicting... or equivalently, how many shares outstanding... when in your mind it might reach $300/sh? I think I have another 20 years or so in me. So may statement is that, unless the company is bought out by then, I will live to see MNNKD at $300/share. It's a swag without any computation or much thought other than if only because of inflation and a product that should produce in excess of $4 billion annual revenue in today's dollars, it seems like an easy bet. However, I do think that $300/share will come sooner than 20 years. Much sooner. Well, just to give some context. Let's assume we tap the current authorized shares, but no further dilution... optimistic but perhaps possible. I think that gets us to 127 million shares. So $300/sh you would be predicting $38 billion market cap. If they truly reach $4 billion annual sales, that isn't stretching valuation into unimaginable realm. That's more aggressive than I'm willing to even hope for at this point... but I'll be thrilled if you're even half correct.
|
|
|
Post by n8 on Oct 10, 2017 16:19:34 GMT -5
The possibility of multiple partnerships, international deals and a drug delivery platform with multiple applications........I would say $300 in under 2 years if not sooner...
|
|
|
Post by dreamboatcruise on Oct 10, 2017 16:23:52 GMT -5
The possibility of multiple partnerships, international deals and a drug delivery platform with multiple applications........I would say $300 in under 2 years if not sooner... So roughly $38 billion market cap by end of first half 2019? How much revenue and profit are you thinking they'll have by then to support $38B market cap?
|
|
|
Post by n8 on Oct 10, 2017 16:31:40 GMT -5
The possibility of multiple partnerships, international deals and a drug delivery platform with multiple applications........I would say $300 in under 2 years if not sooner... So roughly $38 billion market cap by end of first half 2019? How much revenue and profit are you thinking they'll have by then to support $38B market cap? Not sure. Its all relative at this point but the potential is most certainly there. Throw in the possibility of the cannabis market and who knows how fast. My SWAG is is 2 years......ish. Oh and kids not having to have injections that will speed it up also especially if they can get it over the counter.....
|
|
|
Post by celo on Oct 10, 2017 16:32:46 GMT -5
The possibility of multiple partnerships, international deals and a drug delivery platform with multiple applications........I would say $300 in under 2 years if not sooner... So roughly $38 billion market cap by end of first half 2019? How much revenue and profit are you thinking they'll have by then to support $38B market cap? Always realize companies are not necessarily valued at their current revenue/profit but on future possible revenue/profit.
|
|